The NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

A new approach to cancer treatment became available shortly before Jimmy Carter needed it. Now it's a pillar of care.

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

A phase 2 trial investigated the efficacy and safety of nivolumab/ipilimumab in molecularly selected patients with mCRPC, including those with a mismatch repair deficient, high tumor mutational burden ...

Ten years on from their approval, GlobalData reviews their market entry strategies, pricing dynamics over time, and ...

During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and ...

For patients with advanced melanoma, there is a survival benefit for nivolumab plus ipilimumab and for nivolumab monotherapy compared with ipilimumab monotherapy.

Erasca has streamlined its pipeline, now focusing on a phase 3 trial for Naporafenib targeting NRAS-mutant melanoma. Read ...

Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to ...

A huge leap in fine for wrongly using mobility parks, help with childcare costs and access to Keytruda are just some of the ...

In it, they give the example of a cancer drug called nivolumab, which can improve outcomes for patients. In trials – during which people with different 'types' of cancer were included – the drug has ...